Condition: Narcolepsy Type 1 · Sponsor: Alkermes, Inc.
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.
This description comes directly from the study's public registry record.
Director, Clinical Trial Manager · 888-235-8008 (US Only) · clinicaltrials@alkermes.com
Director, Clinical Trial Manager · 571-599-2702 (Global) · clinicaltrials@alkermes.com
Always discuss trial participation with your own doctor first.
| Alkermes Investigational Site | Miami, Florida, United States | Recruiting |
| Alkermes Investigational Site | Winter Park, Florida, United States | Recruiting |
| Alkermes Investigational Site | Atlanta, Georgia, United States | Recruiting |
| Alkermes Investigational Site | Macon, Georgia, United States | Recruiting |
| Alkermes Investigational Site | Lansing, Michigan, United States | Recruiting |
| Alkermes Investigational Site | St Louis, Missouri, United States | Recruiting |
| Alkermes Investigational Site | Cincinnati, Ohio, United States | Recruiting |
| Alkermes Investigational Site | Dallas, Texas, United States | Recruiting |
| Alkermes Investigational Site | San Antonio, Texas, United States | Recruiting |
| Alkermes Investigational Site | Sugar Land, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07540897